Skip to content

Psychedelic-assisted therapy: all studies

Page 204 of 294: studies 2,031 to 2,040 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

A Cohort Based Case Series: Learnings from an Iterative Group Therapy Model to Support Psilocybin-Assisted Therapy for Patients with a Terminal Diagnosis

European Psychiatry April 1, 2024 V. Tsang

Introduction While much is known about psilocybin-assisted therapy for individuals, little is known about the experience of participants in a group psilocybin therapy model. Objectives In an attempt to bridge this gap in the literature, a program development and quality improvement effort was launched. Methods Thirty-one psychedelic-assisted therapy (PaT) sessions were provided for 25...

DOI: 10.1192/j.eurpsy.2024.791 (opens in new tab) Full text (opens in new tab) Terminal diagnoses Unique support Help patients Supports patients +4

The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action

Addiction Biology April 1, 2024 Stephan Tap 12 citations

Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high. Furthermore, there are increases in the treatment gap and few new medications have been approved in the past 20 years. Recently, psychedelic‐assisted therapy with psilocybin and lysergic acid...

The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.

Clinical Toxicology April 1, 2024 Rachael Wilkes, Darren M Roberts, Paul Liknaitzky et al. 8 citations

The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Australia. We aim to describe calls to New South Wales Poisons Information Centre relating to exposures to classical psychedelics including lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, ayahuasca, mescaline and ibogaine. This is a...

Psychedelics: reconnecting the brain to heal the mind

The Biochemist March 25, 2024 David Nutt 3 citations

Natural psychedelics such as magic mushrooms have a long history of human use of at least 7000 years. Their use underwent a resurgence in the 1950/1960s following the synthesis of LSD as a psychedelic and its use as a medicine with powerful therapeutic benefits. But because non-medical use led to massive cultural changes especially in young people, all psychedelics were banned globally in the...

FDA gives breakthrough designation for psychedelic treatment

Mental Health Weekly March 22, 2024 Valerie A. Canady

A clinical‐stage biopharmaceutical company that officials said is committed to revolutionizing mental health care by developing new and innovative next‐generation psychedelic‐based treatment options, announced last week that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for an adjunctive psychedelic‐based therapy for the treatment of major...

Psychedelic Drugs: A Mind-expanding Hallucinogens

Indian Journal of Behavioural Sciences March 22, 2024 Shreyasee Das, Rahul Shil

Psychedelics are mainly from the class of psychoactive substances whose action is to produce changes in the perception, mood, cognitive behavior, and processes of a person. This psychedelic drug creates an alteration in a person’s thinking, sense of time, and emotions. Hallucinations can be a main cause for people who take psychedelics. Mainly, these psychedelic drugs have been used since...

Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression

Journal of Psychopharmacology March 22, 2024 Tommaso Barba, David Erritzøe, Meg J. Spriggs et al. 26 citations

Background: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in...

Is music a drug? How music listening may trigger neurochemical responses in the brain

Musicae Scientiae March 18, 2024 Mark Reybrouck, Edith van Dyck 6 citations

In this article, we explore the idea that music listening can achieve neurological and psychological effects that are somewhat similar to those facilitated by psychoactive substances. To motivate this claim, we delve into the mechanisms behind music perception, psychoactive substance use, and their mutual relationship, relying on recent developments in psychedelic therapy and...

DOI: 10.1177/10298649241236770 (opens in new tab) Neurochemical Neuropsychopharmacology Active listening Pleasure +3

Scanning the new frontier of mental health: psychedelic brain imaging

The Biochemist March 14, 2024 Natalie Ertl, Matthew B. Wall

The use of psychoactive substances for ritual, spiritual and medicinal purposes stretches back into prehistory and has been a common feature of many diverse cultures and societies globally. Psychedelics, with their unique ability to amplify feelings of connectedness and openness, may have also served as tools for promoting tribal cohesion and trust in ancient cultures. Psychedelic is a broad...

DOI: 10.1042/bio_2023_171 (opens in new tab) Full text (opens in new tab) Frontier Brain scanning Mental health Neuroimaging

Pioneering Methods in Brain Optimization and Mental Health Treatment.

ACS Medicinal Chemistry Letters March 14, 2024 Robert B. Kargbo

This Patent Highlight explores ground-breaking advancements in neurostimulation, psychedelic therapy, and brain function optimization from recent innovations. It examines methods for altering brain states through AI-driven non-invasive neurostimulation, potentially contributing to personalized brain therapy. The publication also delves into the therapeutic potential of N-isopropyl tryptamines...

DOI: 10.1021/acsmedchemlett.4c00058 (opens in new tab) Full text (opens in new tab) Psychedelics Artificial intelligence Brain stimulation Mental health